David Blumenthal, MD, MPP, president of The Commonwealth Fund, believes that managed care has lost some of its focus and he would like to see more attention paid to holistic management of care for the frailest, sickest patients.
David Blumenthal, MD, MPP, president of The Commonwealth Fund, believes that managed care has lost some of its focus and he would like to see more attention paid to holistic management of care for the frailest, sickest patients.
Transcript (slightly modified for readability)
What do you expect to see change in managed care in the next 20 years?
The definition of managed care is changing, and what we thought of as managed care, when managed care became a popular term about 20-25 years ago, has a little bit lost its focus. Many, many things have come under the rubric of managed care. For me, managed care means exactly what the term says: it means care that's carefully orchestrated, carefully coordinated, carefully fine-tuned for individuals.
And I think that as we look forward over the next 20 years, given demographic patterns, I hope we'll see much more attention to the holistic management of care for the frailest, sickest, most compromised patients and citizens in our country. I think the management of care for, what we call at The Commonwealth Fund, "high-need, high-cost patients" should be a theme that over the next 20 years gets increasing attention and at which we become really, really expert.
Implicitly, I'm saying that managed care is not maybe a unitary intervention, it's a tailored strategy in which intensive attention is given to how to adapt care to the needs of particular populations.
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Getting to Know Dr Doug Marks, Oncology Clinical Trialist
February 20th 2024Douglas K. Marks, MD, is a breast medical oncologist and director of the Clinical Trials Office, Perlmutter Cancer Center, NYU Langone Hospital—Long Island, as well as associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. As a phase 1 clinical trialist, he sees both patients with breast cancer and those who are looking to receive innovative treatments for their early-stage disease.
Read More